Standout Papers

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge 2022 2026 2023 2024184
  1. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge (2022)
    Ronen Arbel, Yael Wolff Sagy et al. New England Journal of Medicine
  2. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study (2023)
    Ronen Arbel, Alon Peretz et al. The Lancet Infectious Diseases
  3. Real-world effectiveness of a single dose of mpox vaccine in males (2023)
    Yael Wolff Sagy, Ariel Hammerman et al. Nature Medicine

Immediate Impact

50 standout
Sub-graph 1 of 18

Citing Papers

The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) as a predictor of all-cause and cardiovascular mortality in US adults with diabetes or prediabetes: NHANES 1999–2018
2024 Standout
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
2024 Standout
3 intermediate papers

Works of Ronen Arbel being referenced

Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
2022
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
2019

Author Peers

Author Last Decade Papers Cites
Ronen Arbel 86 122 86 368 166 52 759
Lin Gan 48 129 36 287 153 56 765
Joshuan J. Barboza 47 34 75 253 250 92 807
Alagarraju Muthukumar 17 118 75 342 122 35 976
Erez Battat 110 38 51 179 124 24 687
Tal Brosh‐Nissimov 14 14 63 495 94 59 936
Lewis McCurdy 20 38 86 441 162 38 988
Eran Kopel 103 401 126 264 75 47 909
Yang Song 10 58 34 488 92 56 941
Katharina Hartmann 46 26 49 167 153 49 765
E. Aslangul 62 63 115 238 43 33 664

All Works

Loading papers...

Rankless by CCL
2026